Development of O Antigen-based Vaccines Against Q Fever

基于 O 抗原的 Q 热疫苗的开发

基本信息

  • 批准号:
    8582500
  • 负责人:
  • 金额:
    $ 37.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-01 至 2015-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Coxiella burnetii is an obligate intracellular gram-negative bacterium that causes acute Q fever and chronic infections in humans. It is an understudied category B select agent and can be transmitted via aerosol, thus creation of a safe and effective vaccine to prevent Q fever remains an important public health and national biosecurity goal. The long-term goal of this program is to develop new approaches to discover safe, effective vaccines against aerosol-transmitted intracellular bacterial pathogens. The objective of this application, which is an essential step towards this goal, is to identify the epitopes on C. burnetii phase I lipopolysaccharide (PI-LPS) that can confer protection against pulmonary infection with aerosolized C. burnetii. To achieve this objective, we will test the central hypothesis that O antigen of C. burnetii PI-LPS is the key antigen to confer protective immunity against Q fever. The purpose of this proposal is to prove the concept that peptide mimics of protective epitopes on O antigen of PI-LPS can confer protective immunity against C. burnetii infection. The proposal has two specific aims: Aim 1: to determine if O antigen of PI-LPS is the key protective antigen. We will determine if Ab against O antigen of C. burnetii PI-LPS is protective and identify the monoclonal antibodies (mAbs) that can provide protection against C. burnetii infection. We will also determine if purified O antigen from PI-LPS can confer protection against C. burnetii infection. Aim 2: to identify the peptide mimics that can confer protective immunity against C. burnetii infection. We will identify the peptide mimics that can confer protective immunity against C. burnetii infection and determine if peptide mimics of protective epitopes of O antigen can elicit protective immunity against C. burnetii infection. We will also determine if chemically synthesized peptide mimics, in the context of an adjuvant and a suitable delivery system, can provide protection against C. burnetii infection. As an outcome of this research, we expect to prove the concept that peptide mimics of protective epitopes of O antigen can elicit protective immunity against C. burnetii infection. This would have significant positive effects on human health, because it would provide information for vaccine design against Q fever, and in turn lead to development of new strategies to interfere with aerosol transmission of other dangerous intracellular bacterial pathogens.
描述(由申请人提供):伯氏柯克斯体是一种专性细胞内革兰氏阴性细菌,可引起人类急性 Q 热和慢性感染。它是一种正在研究中的 B 类选择病原体,可以通过气溶胶传播,因此开发安全有效的疫苗来预防 Q 热仍然是重要的公共卫生和国家生物安全目标。该计划的长期目标是开发新方法来发现针对气溶胶传播的细胞内细菌病原体的安全、有效的疫苗。本申请的目的是确定伯内特衣原体 I 相脂多糖 (PI-LPS) 上的表位,这是实现这一目标的重要一步,该表位可以提供针对雾化伯内特衣原体肺部感染的保护。为了实现这一目标,我们将检验以下中心假设:伯氏念珠菌 PI-LPS 的 O 抗原是赋予针对 Q 热的保护性免疫力的关键抗原。本提案的目的是证明 PI-LPS O 抗原上的保护性表位的肽模拟物可以赋予针对伯纳特衣原体感染的保护性免疫。该提案有两个具体目标: 目标 1:确定 PI-LPS 的 O 抗原是否是关键的保护性抗原。我们将确定针对伯纳特衣原体 PI-LPS 的 O 抗原的抗体是否具有保护性,并鉴定可提供针对伯纳特衣原体感染的保护的单克隆抗体 (mAb)。我们还将确定从 PI-LPS 中纯化的 O 抗原是否可以提供针对伯内特念珠菌感染的保护作用。目标 2:鉴定能够赋予伯氏念珠菌感染保护性免疫力的肽模拟物。我们将鉴定能够赋予针对伯纳特衣原体感染的保护性免疫的肽模拟物,并确定O抗原保护性表位的肽模拟物是否能够引发针对伯纳特衣原体感染的保护性免疫。我们还将确定化学合成的肽模拟物在佐剂和合适的递送系统的背景下是否可以提供针对伯内特念珠菌感染的保护。作为这项研究的结果,我们期望证明 O 抗原保护性表位的肽模拟物可以引发针对伯纳特衣原体感染的保护性免疫。这将对人类健康产生显着的积极影响,因为它将为针对 Q 热的疫苗设计提供信息,进而导致开发新策略来干扰其他危险的细胞内细菌病原体的气溶胶传播。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Guoquan Zhang其他文献

Guoquan Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Guoquan Zhang', 18)}}的其他基金

Mechanisms of B-1 Cell-Mediated Immunity Against Coxiella burnetii Infection
B-1细胞介导的伯氏柯克斯体感染免疫机制
  • 批准号:
    10155409
  • 财政年份:
    2020
  • 资助金额:
    $ 37.46万
  • 项目类别:
IDENTIFY NOVEL NEUTRALIZATION-SENSITIVE EPITOPES OF COXIELLA BURNETII
鉴定伯内特丘克斯体的新型中和敏感表位
  • 批准号:
    10020119
  • 财政年份:
    2019
  • 资助金额:
    $ 37.46万
  • 项目类别:
Mimetic Peptides-Mediated Protection Against Coxiella burnetii Infection
模拟肽介导的伯氏柯克斯体感染保护
  • 批准号:
    10207396
  • 财政年份:
    2018
  • 资助金额:
    $ 37.46万
  • 项目类别:
Mimetic Peptides-Mediated Protection Against Coxiella burnetii Infection
模拟肽介导的伯氏柯克斯体感染保护
  • 批准号:
    10005679
  • 财政年份:
    2018
  • 资助金额:
    $ 37.46万
  • 项目类别:
Use of a Humanized Antibody against Intracellular Bacterial Pathogen
抗细胞内细菌病原体的人源化抗体的用途
  • 批准号:
    10003580
  • 财政年份:
    2018
  • 资助金额:
    $ 37.46万
  • 项目类别:
Mimetic Peptides-Mediated Protection Against Coxiella burnetii Infection
模拟肽介导的伯氏柯克斯体感染保护
  • 批准号:
    9982219
  • 财政年份:
    2018
  • 资助金额:
    $ 37.46万
  • 项目类别:
ROLE OF DENDRITIC CELLS IN REGULATING VACCINE- INDUCED IMMUNITY AGAINST Q FEVER
树突状细胞在调节疫苗诱导的 Q 热免疫中的作用
  • 批准号:
    10049108
  • 财政年份:
    2018
  • 资助金额:
    $ 37.46万
  • 项目类别:
Mimetic Peptides-Mediated Protection Against Coxiella burnetii Infection
模拟肽介导的伯氏柯克斯体感染保护
  • 批准号:
    9762833
  • 财政年份:
    2018
  • 资助金额:
    $ 37.46万
  • 项目类别:
Development of O Antigen-based Vaccines Against Q Fever
基于 O 抗原的 Q 热疫苗的开发
  • 批准号:
    8386914
  • 财政年份:
    2010
  • 资助金额:
    $ 37.46万
  • 项目类别:
Development of O Antigen-based Vaccines Against Q Fever
基于 O 抗原的 Q 热疫苗的开发
  • 批准号:
    8197349
  • 财政年份:
    2010
  • 资助金额:
    $ 37.46万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 37.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了